Allergan rejects improved offer from Valeant

10 June 2014 - Deborah Wilkes

Archived

Allergan has rejected a revised offer from Pershing Square Capital Management and Valeant Pharmaceuticals International that values the Botox maker at around US$53 billion.

Click tags below for more information on topics:

Bausch Health

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: